August 08, 2011
A Texas federal judge ruled Friday that Par Pharmaceutical Cos. Inc. and two other drugmakers had infringed Pozen Inc.'s patents covering the migraine treatment Treximet and barred them from selling generic versions of the drug in the U.S. until certain patents expire.
April 15, 2011
A Texas federal judge on Thursday barred Par Pharmaceutical Cos. Inc. from selling a generic version of Pozen Inc. migraine treatment Treximet in the U.S. until a patent infringement battle over the drug is resolved.